Cancer and heart disease are the two most common causes of death in developed countries. Each disease considered separately should be thought of as a complex group of related diseases. Considering them in combination greatly heightens the complexity of what we speak of as cancer and heart disease. Great progress has been made in treatment, early diagnosis, and prevention of these diseases; yet both remain extraordinary concerns from both a public health perspective and with regard to the devastation and suffering that those afflicted with a dual diagnosis of cancer and cardiotoxicity must endure.
This second edition of Cancer and the Heart covers the complex interactions of multiple diseases in patients who have cancer and who either have or are expected to acquire significant heart disease. Information on the subject is often fragmented or not presented in a concise format; we believe that this updated revision will facilitate personalized clinical management and provide the basic background to support clinical decision-making.

Key Features:

– Provides a synthesis of the most relevant information regarding the treatment and disease progression of patients with the dual diagnosis of cancer and heart disease.
– A current and comprehensive reference for clinicians, investigators, and students
– Include over 200 illustrations, many of which are in full color.
– Detailed Table of Contents and Index highlight important concepts.

About the Author

Michael S. Ewer, M.D., M.P.H., J.D., is Professor of Medicine at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He received his medical degree from the University of Basel in Switzerland and was a cardiology fellow at Baylor University Medical Center in Dallas, Texas. His clinical and research interests include cardiotoxicity of anthracyclines, trastuzumab cardiotoxicity, and ethical and legal concerns with regard to cancer patients. Edward T.H. Yeh, M.D., is Professor of Medicine and Chair, Department of Cardiology at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He received his medical degree from the University of California at Davis, and he was a cardiology fellow at the University of Texas Houston Health Science Center. His clinical and research interests include the role of inflammation in the development of coronary artery disease; cardiac complications of anti-cancer therapy; stem cell transplant for congestive heart failure; and ubiquitin, ubiquitin-like proteins, and cancer.

Contents

Principles of Oncologic Chemotherapy and Immunotherapy
Anthracydine Cardiotoxicity: Clinical Aspects, Recognition, Monitoring, Treatment, and Prevention
Anthracydine-Induced Cardiotoxicity: Paradigm Lost and Regained
Trastuzumab-Associated Cardiotoxicity
Cardiotoxicity of Tyrosine-Kinase Inhibitors
Cardiotoxicity of Other Anti-Cancer Treatment
Effects of Radiation Therapy on the Cardiovascular System
Cardiac Considerations in the Treatment of Cancer in Infants and Children
Peripheral Arterial Disease in Cancer Patients
Cardiac Ultrasound, Doppler Imaging, and Related Techniques in the Cancer Patient
Cardiac Arrhythmias in the Cancer Patient
Heart Failure in the Cancer Patient
Cardiac Interventions in Cancer Patients
Cardiac Emergencies in Cancer Patients
Preoperative Assessment of the Cancer Patient for Noncardiovascular Surgery
Pericardial Disease in the Cancer Patient
The Impact of Adjuvant Endocrine Therapy on Cardiovascular Disease of Breast Cancer Patients*
Surgical Approach to Cardiac Tumors
Cardiac Monitoring During Clinical Trials
Legal, Social, and Economic Issues for Cancer Patients with Heart Disease*
Heart-Lung Interactions in the Cancer Patient
Psychosocial Considerations in the Cancer Patient with Heart Disease
Cardiac Amyloid and Carcinoid Heart Disease